Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.

Similarly, Barraclough et al. showed that canagliflozin consistently decreased the risk of major CV and kidney outcomes in patients with T2D, regardless of PAD status at baseline. The MACE benefit with canagliflozin in individuals with T2D, CKD and PAD translates into an ARR of -26.0 events/1000 patients over 2.5 years versus placebo. [Extracted from the article]